Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Analysts at Wedbush decreased their FY2017 earnings per share (EPS) estimates for Global Blood Therapeutics in a report issued on Monday. Wedbush analyst L. Moussatos now expects that the company will post earnings of ($2.51) per share for the year, down from their previous estimate of ($2.34). Wedbush has a “Outperform” rating and a $73.00 price target on the stock. Wedbush also issued estimates for Global Blood Therapeutics’ Q4 2017 earnings at ($0.69) EPS, FY2018 earnings at ($2.99) EPS, FY2019 earnings at ($3.77) EPS, FY2020 earnings at ($3.39) EPS and FY2021 earnings at ($1.56) EPS.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period last year, the company earned ($0.58) EPS.
Global Blood Therapeutics (NASDAQ GBT) opened at $43.85 on Wednesday. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $44.30.
A number of institutional investors and hedge funds have recently bought and sold shares of GBT. BNP Paribas Arbitrage SA grew its stake in Global Blood Therapeutics by 694.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after acquiring an additional 3,975 shares in the last quarter. Legal & General Group Plc grew its stake in Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after acquiring an additional 440 shares in the last quarter. Jane Street Group LLC purchased a new position in Global Blood Therapeutics during the third quarter valued at $200,000. Trexquant Investment LP purchased a new position in Global Blood Therapeutics during the third quarter valued at $202,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Global Blood Therapeutics during the third quarter valued at $205,000. 90.48% of the stock is owned by institutional investors.
In other news, VP Peter Radovich sold 12,500 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the sale, the insider now directly owns 140,055 shares of the company’s stock, valued at $4,201,650. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,500 shares of company stock valued at $3,003,350. 5.30% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.chaffeybreeze.com/2017/12/08/brokers-set-expectations-for-global-blood-therapeutics-inc-s-fy2017-earnings-gbt.html.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.